Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
Giuseppe Cabibbo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Calogero Cammà(Department of Health), Salvatore Guastella(University of Palermo), Anna Licata(University of Palermo), F. Benanti(Ospedale Garibaldi), Vincenza Calvaruso(University of Palermo), Ciro Celsa(Department of Health), Gaetano Bertino, Giovanni Mazzola(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Franco Trevisani(Italian Association for Cancer Research), Salvatore Madonia(Ospedale Vincenzo Cervello), F. Cartabellotta(Ospedale Buccheri la Ferla Fatebenefratelli), Maurizio Russello(Ospedale Garibaldi), V. Di Marco(University of Palermo), Tullio Prestileo, Nicola Alessi(University of Palermo), Giovanni Squadrito(University of Messina), Giovanni Raimondo(University of Messina), A. Averna, M. Rossi(University of Palermo), Salvatore Petta(University of Palermo), Bianca Magro(University of Palermo), Irene Cacciola(University of Messina), Maria Antonietta Di Rosolini(Azienda Unita' Sanitaria Locale Di Modena), Giuseppe Alaimo, Antonio Craxı̀(University of Palermo), M.R. Cannavò(Ospedale Garibaldi), Licia Larocca, Gaetano Scifo(Ospedali Riuniti Umberto I), Marco Distefano(Ospedali Riuniti Umberto I), Giuseppe Malizia(Ospedale Vincenzo Cervello), Francesca Rini(University of Palermo), I. Scalisi
Cited by 205
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
|Hepatology|2017|657